Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation

被引:12
|
作者
Webster-Clark, Michael [1 ]
Lund, Jennifer L. [1 ]
Sturmer, Til [1 ]
Poole, Charles [1 ]
Simpson, Ross J. [2 ]
Edwards, Jessie K. [1 ]
机构
[1] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA
基金
美国国家卫生研究院;
关键词
Anticoagulation; Generalizability; Medicare; Older adults; Transportability; CLINICAL-TRIALS; ORAL ANTICOAGULANTS; STROKE PREVENTION; ADVERSE EVENTS; WARFARIN; DABIGATRAN; RIVAROXABAN; APIXABAN; OUTCOMES; THERAPY;
D O I
10.1097/EDE.0000000000001230
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Results from trials and nonexperimental studies are often directly compared, with little attention paid to differences between study populations. When target and trial population data are available, accounting for these differences through transporting trial results to target populations of interest provides useful perspective. We aimed to compare two-year risk differences (RDs) for ischemic stroke, mortality, and gastrointestinal bleeding in older adults with atrial fibrillation initiating dabigatran and warfarin when using trial transport methods versus nonexperimental methods. Methods: We identified Medicare beneficiaries who initiated warfarin or dabigatran from a 20% nationwide sample. To transport treatment effects observed in the randomized evaluation of long-term anticoagulation trial, we applied inverse odds weights to standardize estimates to two Medicare target populations of interest, initiators of: (1) dabigatran and (2) warfarin. Separately, we conducted a nonexperimental study in the Medicare populations using standardized morbidity ratio weighting to control measured confounding. Results: Comparing dabigatran to warfarin, estimated two-year RDs for ischemic stroke were similar with trial transport and nonexperimental methods. However, two-year mortality RDs were closer to the null when using trial transport versus nonexperimental methods for the dabigatran target population (transported RD: -0.57%; nonexperimental RD: -1.9%). Estimated gastrointestinal bleeding RDs from trial transport (dabigatran initiator RD: 1.8%; warfarin initiator RD: 1.9%) appeared more harmful than nonexperimental results (dabigatran initiator RD: 0.14%; warfarin initiator RD: 0.57%). Conclusions: Differences in study populations can and should be considered quantitatively to ensure results are relevant to populations of interest, particularly when comparing trial with nonexperimental findings. See video abstract:.
引用
收藏
页码:605 / 613
页数:9
相关论文
共 50 条
  • [21] Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial
    Proietti, M.
    Hijazi, Z.
    Andersson, U.
    Connolly, S. J.
    Eikelboom, J. W.
    Ezekowitz, M. D.
    Lane, D. A.
    Oldgren, J.
    Roldan, V.
    Yusuf, S.
    Wallentin, L.
    JOURNAL OF INTERNAL MEDICINE, 2018, 283 (03) : 282 - 292
  • [22] Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial
    Westenbrink, B. Daan
    Alings, Marco
    Connolly, Stuart
    Eikelboom, Iohn
    Ezekowitz, Michael D.
    Oldgren, Jonas
    Yang, Sean
    Pogue, Janice
    Yusuf, Salim
    Wallentin, Lars
    van Gilst, Wiek H.
    CIRCULATION, 2012, 126 (21)
  • [23] Letter by Freeman et al Regarding Article, "Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial"
    Freeman, W. David
    Kuo, Ruth
    Aguilar, Maria I.
    STROKE, 2012, 43 (07) : E63 - E63
  • [24] DABIGATRAN ETEXILATE VERSUS WARFARIN IN PATIENTS WITH DIFFERENT TYPES OF ATRIAL FIBRILLATION: A RE-LY® SUBGROUP ANALYSIS
    Flaker, Greg C.
    Reilly, Paul
    Yusuf, Salim
    Ezekowitz, Mike
    Wallentin, Lars
    Brueckmann, Martina
    Connolly, Stuart
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E62 - E62
  • [25] Recurrent Events and Mortality Among Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the RE-LY Trial
    Diener, H. C.
    Marijon, E.
    Le Heuzey, J. -Y.
    Connolly, S.
    Noack, H.
    Brueckmann, M.
    Eikelboom, J.
    Ezekowitz, M.
    Clemens, A.
    Reilly, P.
    Wallentin, L.
    Yusuf, S.
    CEREBROVASCULAR DISEASES, 2013, 35 : 165 - 165
  • [26] Stroke-Related Specific Mortality and Influencing Factors in Patients with Atrial Fibrillation in the RE-LY Trial
    Le Heuzey, Jean-Yves
    Marijon, Eloi
    Connolly, Stuart
    Brueckmann, Martina
    Yang, Sean
    Pogue, Janice
    Eikelboom, John
    Ezekowitz, Michael
    Themeles, Ellison
    Wallentin, Lars
    Yusuf, Salim
    STROKE, 2013, 44 (02)
  • [27] Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Yang, Sean
    Wallentin, Lars
    Ezekowitz, Michael
    Reilly, Paul
    Eikelboom, John
    Brueckmann, Martina
    Yusuf, Salim
    Connolly, Stuart J.
    CIRCULATION, 2012, 125 (05) : 669 - 676
  • [28] Review of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial: Warfarin versus dabigatran
    Ingelmo C.
    Wazni O.
    Current Cardiology Reports, 2011, 13 (5) : 357 - 360
  • [29] Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial
    Ferreira, Jorge
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Brueckmann, Martina
    Fraessdorf, Mandy
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (09) : 1053 - 1061
  • [30] Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial
    Alak, Aiman
    Hohnloser, Stefan H.
    Fraessdorf, Mandy
    Reilly, Paul
    Ezekowitz, Michael
    Healey, Jeff S.
    Brueckmann, Martina
    Yusuf, Salim
    Connolly, Stuart J.
    EUROPACE, 2019, 21 (07): : 1023 - 1038